By Annisa Sofia 
Fred Hutch Cancer Center researchers have made a significant advance in the effort to block Epstein-Barr virus (EBV), a widespread infection that affects about 95% of people worldwide and is linked to several cancers, neurodegenerative conditions, and other long-term illnesses. This groundbreaking work, detailed in the journal Cell Reports Medicine, introduces a novel strategy employing human monoclonal antibodies engineered to neutralize the virus at its initial point of entry into the human immune system. The development offers a beacon of hope, particularly for vulnerable patient populations such as organ transplant recipients who face severe health risks due to EBV reactivation.
The research team’s innovative approach involved leveraging mice genetically engineered to produce human antibodies. This sophisticated model allowed scientists to generate a new arsenal of monoclonal antibodies specifically designed to prevent EBV from attaching to and subsequently entering human immune cells, primarily B cells. In rigorous testing, one of these newly developed antibodies demonstrated a remarkable ability to completely prevent EBV infection in mice possessing human-like immune systems when they were exposed to the virus. This outcome represents a substantial leap forward in the long-standing scientific quest to control a ubiquitous pathogen that has historically evaded effective therapeutic intervention.
The Persistent Challenge of EBV Neutralization
Epstein-Barr virus, a member of the herpesvirus family, establishes lifelong infections in the majority of the global population, often asymptomatically. However, its latent presence can be reactivated under conditions of immune suppression, leading to a cascade of serious health complications. These include various lymphomas, such as post-transplant lymphoproliferative disorder (PTLD), as well as being implicated in the development or exacerbation of conditions like multiple sclerosis, autoimmune diseases, and certain gastrointestinal cancers.
Dr. Andrew McGuire, a biochemist and cellular biologist within Fred Hutch’s Vaccine and Infectious Disease Division, highlighted the unique difficulties in developing EBV-blocking therapies. "Finding human antibodies that block Epstein Barr virus from infecting our immune cells has been particularly challenging because, unlike other viruses, EBV finds a way to bind to nearly every one of our B cells," Dr. McGuire explained. He further elaborated on the scientific impetus behind their work: "We decided to use new technologies to try to fill this knowledge gap, and we ended up taking a critical step toward blocking one of the world’s most common viruses."
A significant hurdle in antibody-based antiviral therapies, especially those derived from non-human sources, is the potential for the human immune system to recognize these antibodies as foreign and mount an immune response against them. This can render the therapy ineffective and potentially dangerous. The Fred Hutch team circumvented this issue by focusing on developing human antibodies from the outset, utilizing their specialized mouse model to elicit a robust human antibody response against EBV.
Targeting Viral Entry: A Dual-Pronged Antibody Strategy
The researchers strategically focused their efforts on two key viral surface proteins that are critical for EBV’s infectious process: glycoprotein 350 (gp350) and glycoprotein 42 (gp42). The gp350 protein serves as the initial docking point, enabling the virus to attach to the surface of susceptible human cells, primarily B cells. Following attachment, the gp42 protein plays a crucial role in mediating the fusion of the viral envelope with the cell membrane, thereby facilitating the virus’s entry into the cell. By targeting these essential components, the developed antibodies aim to disrupt the viral lifecycle before it can establish an infection.
Employing their genetically modified mouse model, the scientists successfully identified a promising panel of monoclonal antibodies. Their screening process yielded two distinct antibodies that effectively bind to and neutralize the gp350 protein, and a larger set of eight antibodies that target the gp42 protein. This comprehensive identification of multiple antibody candidates targeting different viral entry mechanisms provides a robust foundation for further development and optimization.
Crystal Chhan, a pathobiology PhD student in the McGuire Lab, expressed her enthusiasm for the findings and the broader implications of their research methodology. "Not only did we identify important antibodies against Epstein Barr virus, but we also validated an innovative new approach for discovering protective antibodies against other pathogens," Chhan stated. Reflecting on her experience as an early-career scientist, she added, "As an early-career scientist, it was an exciting finding and has helped me appreciate how science often leads to unexpected discoveries."
Unveiling Viral Weaknesses and Promising Candidates
Further in-depth analysis, significantly aided by the resources and expertise of Fred Hutch’s Antibody Tech Core, provided critical insights into the specific structural vulnerabilities on the EBV virus targeted by these antibodies. This detailed understanding of the interaction between the antibodies and their viral targets not only validates the efficacy of the discovered antibodies but also offers invaluable guidance for future vaccine design, potentially leading to more broadly protective EBV vaccines.
In the final stages of preclinical testing, the performance of the most promising antibody candidates was rigorously assessed. The results were highly encouraging: one of the gp42-targeting antibodies demonstrated the capacity to completely block EBV infection in the experimental model. Concurrently, an antibody directed against gp350 provided significant partial protection, underscoring the potential of targeting both viral entry proteins for a more comprehensive defensive strategy.
A Critical Need: Protecting Transplant Recipients
The implications of this research are particularly profound for individuals undergoing solid organ or bone marrow transplantation. In the United States alone, over 128,000 such procedures are performed annually. These life-saving interventions necessitate the use of immunosuppressive drugs to prevent organ rejection. However, this essential immunosuppression creates a precarious environment where latent viruses, such as EBV, can reactivate and proliferate unchecked, posing a significant threat to the patient’s health and the success of the transplant.
Currently, there are no specific prophylactic therapies available to prevent EBV reactivation or infection in transplant recipients. This absence of targeted prevention leaves a critical unmet need in transplant medicine. A major complication arising from uncontrolled EBV activity in this population is post-transplant lymphoproliferative disorders (PTLD). PTLD is a serious, and often life-threatening, form of lymphoma that can develop after transplantation, predominantly driven by the uncontrolled proliferation of B cells infected by EBV.
Dr. Rachel Bender Ignacio, an associate professor and infectious disease physician at Fred Hutch and the University of Washington School of Medicine, emphasized the critical importance of addressing EBV in transplant patients. "Post-transplant lymphoproliferative disorders (PTLD), most of which are EBV-associated lymphomas, are a frequent cause of morbidity and mortality after organ transplantation," Dr. Bender Ignacio noted. She further elaborated on the potential impact of the new findings: "Preventing EBV viremia has strong potential to reduce the incidence of PTLD and limit the need to reduce immunosuppression, thereby helping preserve graft function while improving overall patient outcomes. Effective prevention of EBV viremia remains a significant unmet need in transplant medicine."
The risk of EBV exposure for transplant patients can arise from various sources. Donor organs themselves can harbor a latent form of the virus, which can then become active in the immunosuppressed recipient. For individuals who have previously been infected with EBV, their own latent virus can reactivate and multiply due to the diminished immune surveillance. Children undergoing transplantation are a particularly vulnerable group, as many have not yet been exposed to EBV and are therefore more susceptible to primary infection and its subsequent complications when immunosuppressed.
Paving the Way for a Preventive Antibody Therapy
The Fred Hutch research team envisions a future where these newly developed human monoclonal antibodies can be administered as a preventive measure, likely through infusion. This therapeutic strategy would be particularly beneficial for high-risk individuals, including transplant recipients, to preemptively block EBV infection or prevent the reactivation of latent virus. By interrupting the virus’s ability to infect cells early in its lifecycle, such a therapy could significantly reduce the incidence of devastating complications like PTLD and other EBV-related morbidities.
Fred Hutch has taken steps to protect its intellectual property related to these novel antibody discoveries by filing patent applications. Dr. McGuire and Chhan are actively collaborating with other researchers and an industry partner to accelerate the translation of this promising research from the laboratory bench to clinical application. The immediate next steps in this progression are likely to involve rigorous safety testing in healthy adult volunteers. Following successful safety evaluations, the research would proceed to clinical trials designed to assess the efficacy and safety of the antibody therapy in patient populations at the highest risk of EBV-related complications.
"There’s momentum to advance our discovery to a therapy that would make a huge difference for patients undergoing transplant," stated Dr. McGuire. He concluded with a forward-looking perspective on the significance of their work: "After many years of searching for a viable way to protect against Epstein Barr virus, this is a significant stride for the scientific community and the people at the highest risk of complications from this virus." The successful development of such a therapy could fundamentally alter the landscape of care for transplant recipients and potentially for individuals suffering from other EBV-associated conditions, marking a new era in the fight against this pervasive and often insidious virus.